EliteG Infinite Compound Project

[la-onda]

GLIF is flying high 

[OneStockMind]

Hm... Iright now DOMS is .30 on the buy side and .50 on the sell. That's QUITE a spread.

[REALDEALS21]

Anyone still holding HYRF ?

[eliteG]

Since I posted all my buys for GLIF(.0269, .0360, .0260 = avg .030) I need to post that I sold half here @ .042(+40% ) just to free up cash/bring home the bacon.. My position was a bit too big for my comfort level 

If closes above .036 it will confirm the hammer as a potential strong reversal and not just support.  A close above .04 is crazy bullish as that is in the upper shadow(an area where price was rejected before) of the huge run earlier.  Above .046 thats a G-pattern breakout.. 

C'mon Gliffy! 

[eliteG]

I am not playing anything till tomorrow but this one looks interesting.. check it out 

LBTN.pk - looks similar to ADDI's G-pattern breakout a while back.. might be a good overnighter.  I think it may have more to give.

[catrader]

I am not playing anything till tomorrow but this one looks interesting.. check it out 

LBTN.pk - looks similar to ADDI's G-pattern breakout a while back.. might be a good overnighter.  I think it may have more to give.

lbtn now at 0.015 +.008 or 114% on the day, the spread I see is 0.014 x0.016 or almost 15%.  considering the run up and spred, would you say this is a high risk,  ??  reward investment?

[la-onda]

nice chart

[OneStockMind]

Symmetric triangle on GLIF intraday chart again.

[runforthedoor]

  SRGX....contract news pending...buy while it's cheap.

http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cbw%5C2005%5C10%5C27%5C71768174.html%26clientid%3D168%26provider%3DBUSINESS_WIRE&symbol=SRGX

[eliteG]

I am not playing anything till tomorrow but this one looks interesting.. check it out 

LBTN.pk - looks similar to ADDI's G-pattern breakout a while back.. might be a good overnighter.  I think it may have more to give.

lbtn now at 0.015 +.008 or 114% on the day, the spread I see is 0.014 x0.016 or almost 15%.  considering the run up and spred, would you say this is a high risk,  ??  reward investment?

I would not buy @ the ask on it.. but like la-onda says nice chart.. has potential to make a nice home for some capital for a short time

Symmetric triangle on GLIF intraday chart again.

I think you meant ascending triangle.  Whatever it is its showing strength.  rock on.

SRGX....contract news pending...buy while it's cheap.

http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cbw%5C2005%5C10%5C27%5C71768174.html%26clientid%3D168%26provider%3DBUSINESS_WIRE&symbol=SRGX

I'll keep an eye Run. thx but at this point I do not like it yet.

[OneStockMind]

Ascending triangle.. Thanks Elite. I'm a bit dizzy from HYRF today.. still cannot believe it happened and then it went up to .40 while Scottish and I got out at .255.
Just bad luck all over. I REALLY hope GLIF will take me out of this mud.

[MarketMakerz]

Ascending triangle.. Thanks Elite. I'm a bit dizzy from HYRF today.. still cannot believe it happened and then it went up to .40 while Scottish and I got out at .255.
Just bad luck all over. I REALLY hope GLIF will take me out of this mud.

Bulls are in control here stockmind...watch each week we continue making higher highs and higher lows. I think you have a pretty good chance of recovering money lost in HYRF over here...plus some intrest. 

GLIF is a multi bagger.

[catrader]

would vrde at 0.055 up 50% in the day look good to you based on the following news or any other indicator you see?  http://biz.yahoo.com/bw/051027/275790.html?.v=1 .  bought small stake here.

[OneStockMind]

Yes Market, I hope your words go directly to God's ears (especially that .25 in a month)

[la-onda]

added more GLIFs 

why?

rant Life Sciences (OTCBB: GLIF - http://finance.yahoo.com/q?s=GLIF.OB )

Grant Life Sciences announced that it expects to begin generating revenues this year, possibly within 30 days, on sales of its rapid tests for Malaria and Dengue Fever. These products, along with rapid tests for HIV-1 and HIV-2, were acquired earlier this year from AccuDx Corp., a biotechnology company based in La Jolla, Calif., founded by Ravi Pottahil, Ph.D., one of the world's leading authorities in the field of HIV/AIDS diagnostics and therapeutics. (Dr. Pottahil was the section manager for retroviruses and tumor markers and PCR diagnostics at Hoffman-La Roche from 1985 to 1992, when he co-founded Specialty BioSystems with Specialty Laboratories, one of the largest independent reference laboratories in California. Dr. Pottathil also was an advisor to the World Health Organization's Sexually Transmitted Diseases and Global Vaccination program.)

Under the agreement with AccuDx, Grant Life Sciences controls the exclusive rights to AccuDx's rapid tests, as well as AccuDx's proprietary colloidal gold reagent. In addition, the agreement established the right for Grant Life Sciences to manufacture these products in AccuDx's 'maquiladora'-modeled contract facility in Tijuana, Mexico, which is registered with the FDA and is ISO 9002-certified. Dr. Pottahil is assisting Grant Life Sciences in expanding its product line to include rapid tests for Hepatitis, Rubella, and other common diseases.

"We are very pleased to report that Grant Life Sciences has been successful in re-establishing the first of several distribution channels previously utilized by AccuDx," said Dr. Hun-Chi Lin, President and Chief Scientist at Grant Life Sciences. "Indeed, we expect to have a working marketing-and-sales mechanism in place prior to the approval necessary for us distribute our blood tests in all of the major foreign markets," added Dr. Lin. "While we are very excited by the opportunity to begin generating revenues soon, this situation also solidly positions Grant Life Sciences for the eventual manufacturing and distribution of our core product, the immunological serum-based test for detecting Cervical Cancer and its precursors," Dr. Lin concluded.

"Having our manufacturing operations in place and our distribution channels ready is the most significant milestone yet for Grant Life Sciences," said Stan Yakatan, Chairman of Grant Life Sciences. "Being able to generate revenues from our products in specialty diagnostic markets outside of the U.S. will provide us with some of the resources necessary to move us forward with the clinical validation of our core product, a rapid test for detecting cervical cancer."
link:
http://www.knobias.com/individual/public/news.htm?eid=3.1.f6d1dae479b6a7913aeb6ed82a6b4633a4d07959bbf7bbb04cf6073ee1d59e2f